Drugs / ILB-202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05843799 | May → Oct 2023 | — | ILIAS Biologics Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2025-09-29 | ILIAS Biologics Inc. | Results ILIAS Biologics Publishes Exosome-Based New Drug ILB-202 Results in International Journal iliasbio.com ↗
ILB-202 was also confirmed to have differentiated action properties that target only pathologically excessively increased inflammation while maintaining physiological immunity. |
| 2024-10-26 | ILIAS Biologics Inc. | Results "Prepare a clinical paper on anti-inflammatory drugs...Planning to post next year" iliasbio.com ↗
As a result of blood analysis, we have found a type (pattern) that can see the effectiveness of drugs in inflammatory cells and are preparing this as a thesis. |
| 2024-07-23 | ILIAS Biologics Inc. | Results ILIAS Biologics Secures Phase 1 Results of Exosome Treatment and Announces International Journal of Academic Journal iliasbio.com ↗
'ILB-202,' indicates a higher expected safety compared to existing anti-inflammatory treatments. |
| 2024-06-11 | ILIAS Biologics Inc. | Results ILIAS Biologics Receives 'One More Step' Australian Phase 1 Clinical Report Of Anti-Inflammatory Exosome Treatment 'ILB-202' Before Global Technology iliasbio.com ↗
ILIAS Biologics Co., Ltd. (CEO Choi Chul-hee, hereinafter ILIAS) received the final result report (Clinical Study Report, CSR) of the phase 1 clinical trial of ILB-202, a company's leading pipeline exosome treatment completed in Australia in November last year. |
| 2022-05-24 | ILIAS Biologics Inc. | Results Researchers of ILIAS published biodistribution and pharmacokinetics study of ILB-202 in Pharmaceutics iliasbio.com ↗
Studies have shown that exosomes are mainly distributed in the liver, spleen, and kidney but are rapidly cleared from the blood circulation. |
| 2022-04-08 | ILIAS Biologics Inc. | Regulatory ILIAS Biologics Receives HREC Approval to Initiate First-in-Human Clinical Trial of ILB-202 iliasbio.com ↗
With the approval to initiate the first-in-human clinical trial of ILB 202, we are one step closer to developing novel exosome-based therapeutics to help patients in need. |
| 2022-03-14 | ILIAS Biologics Inc. | Regulatory Chulhee Choi, Co-CEO of ILIAS, interviewed Hankyung iliasbio.com ↗
ILIAS submitted a phase 1 clinical trial plan (IND) of the lead pipeline, ‘ILB-202’, to the Australian Food and Drug Administration (TGA) in February. |
All press releases naming this drug 8 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ILB-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05843799 ↗ |
| Action | Inhibit | “Safety and Anti-Inflammatory Effects of Engineered Extracellular Vesicles (ILB-202) for NF-κB Inhibition” PMID 41002119 ↗ Sep 2025 |
| Modality | Other / unclassified | “an engineered, allogeneic EV derived from HEK293 cells” PMID 41002119 ↗ Sep 2025 |
| Route | Intravenous | “A single ascending intravenous dose of ILB-202 was administered to 18 healthy volunteers” PMID 41002119 ↗ Sep 2025 |